CYLD negatively regulates nontypeable haemophilus influenzae-induced IL-8 expression via phosphatase MKP-1-dependent inhibition of ERK

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Wang, Wenzhuo Y ^a,b   Komatsu, Kensei ^a   Huang, Yuxian ^c,d   Wu, Jing ^c   Zhang, Wenhong ^c   Lee, Ji Yun ^a   Miyata, Masanori ^a   Xu, Haidong ^a   Li, Jian Dong ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DEUBIQUITINASE; DEUBIQUITINASE CYLINDROMATOSIS; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; UNCLASSIFIED DRUG; CYLD PROTEIN, HUMAN; CYLD PROTEIN, MOUSE; CYSTEINE PROTEINASE; DUSP1 PROTEIN, HUMAN; MAPK1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TUMOR SUPPRESSOR PROTEIN;

A549 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; INFLAMMATION; KNOCKOUT MOUSE; LUNG ALVEOLUS EPITHELIUM; MOUSE; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; PROTEIN EXPRESSION; PROTEIN TARGETING; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; GENE EXPRESSION REGULATION; GENETICS; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HELA CELL LINE; HOST PATHOGEN INTERACTION; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

HAEMOPHILUS INFLUENZAE;

ANIMALS; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DUAL SPECIFICITY PHOSPHATASE 1; GENE EXPRESSION REGULATION; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HELA CELLS; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERLEUKIN-8; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84911363908     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112516     Document Type: Article

References (44)

1. Foxwell AR, Kyd JM, Cripps AW (1998) Nontypeable Haemophilus influenzae: pathogenesis and prevention. Microbiol Mol Biol Rev 62: 294-308.
2. Chartrand SA, Pong A (1998) Acute otitis media in the 1990s: the impact of antibiotic resistance. Pediatr Ann 27: 86-95.
3. Gates GA (1996) Cost-effectiveness considerations in otitis media treatment. Otolaryngol Head Neck Surg 114: 525-530.
4. Minino AM, Arias E, Kochanek KD, Murphy SL, Smith BL (2002) Deaths: final data for 2000. Natl Vital Stat Rep 50: 1-119.
5. Rubinstein AL, Irazola VE, Bazzano LA, Sobrino E, Calandrelli M, et al. (2011) Detection and follow-up of chronic obstructive pulmonary disease (COPD) and risk factors in the Southern Cone of Latin America: the pulmonary risk in South America (PRISA) study. BMC Pulm Med 11: 34.
6. Arguedas A, Kvaerner K, Liese J, Schilder AG, Pelton SI (2010) Otitis media across nine countries: disease burden and management. Int J Pediatr Otorhinolaryngol 74: 1419-1424.
7. Ito M, Hotomi M, Maruyama Y, Hatano M, Sugimoto H, et al. (2010) Clonal spread of beta-lactamase-producing amoxicillin-clavulanate-resistant (BLPACR) strains of non-typeable Haemophilus influenzae among young children attending a day care in Japan. Int J Pediatr Otorhinolaryngol 74: 901-906.
8. Shuto T, Xu H, Wang B, Han J, Kai H, et al. (2001) Activation of NF-kappa B by nontypeable Hemophilus influenzae is mediated by toll-like receptor 2- TAK1-dependent NIK-IKK alpha/beta-I kappa B alpha and MKK3/6-p38 MAP kinase signaling pathways in epithelial cells. Proc Natl Acad Sci U S A 98: 8774-8779.
9. de Oliveira S, Reyes-Aldasoro CC, Candel S, Renshaw SA, Mulero V, et al. (2013) Cxcl8 (IL-8) mediates neutrophil recruitment and behavior in the zebrafish inflammatory response. J Immunol 190: 4349-4359.
10. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454: 428-435.
11. Wang B, Cleary PP, Xu H, Li JD (2003) Up-regulation of interleukin-8 by novel small cytoplasmic molecules of nontypeable Haemophilus influenzae via p38 and extracellular signal-regulated kinase pathways. Infect Immun 71: 5523-5530.
12. Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, et al. (2003) Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 17: 1263-1293.
13. Ludwig S (2009) Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy. J Antimicrob Chemother 64: 1-4.
14. Poulikakos PI, Solit DB (2011) Resistance to MEK inhibitors: should we cotarget upstream? Sci Signal 4: pe16.
15. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, et al. (1999) Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5: 810-816.
16. Jono H, Lim JH, Chen LF, Xu H, Trompouki E, et al. (2004) NF-kappaB is essential for induction of CYLD, the negative regulator of NF-kappaB: evidence for a novel inducible autoregulatory feedback pathway. J Biol Chem 279: 36171-36174.
17. Lim JH, Jono H, Koga T, Woo CH, Ishinaga H, et al. (2007) Tumor suppressor CYLD acts as a negative regulator for non-typeable Haemophilus influenzainduced inflammation in the middle ear and lung of mice. PLoS One 2: e1032.
18. Sun SC (2008) Deubiquitylation and regulation of the immune response. Nat Rev Immunol 8: 501-511.
19. Wang WY, Lim JH, Li JD (2012) Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections. Cell Mol Immunol 9: 131-135.
20. Lim JH, Jono H, Komatsu K, Woo CH, Lee J, et al. (2012) CYLD negatively regulates transforming growth factor-beta-signalling via deubiquitinating Akt. Nat Commun 3: 771.
21. Lim JH, Stirling B, Derry J, Koga T, Jono H, et al. (2007) Tumor suppressor CYLD regulates acute lung injury in lethal Streptococcus pneumoniae infections. Immunity 27: 349-360.
22. Yoshida H, Jono H, Kai H, Li JD (2005) The tumor suppressor cylindromatosis (CYLD) acts as a negative regulator for toll-like receptor 2 signaling via negative cross-talk with TRAF6 AND TRAF7. J Biol Chem 280: 41111-41121.
23. Reiley W, Zhang M, Sun SC (2004) Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 279: 55161-55167.
24. Komatsu K, Lee JY, Miyata M, Lim JH, Jono H, et al. (2013) Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. Nat Commun 4: 1684.
25. Sakai A, Koga T, Lim JH, Jono H, Harada K, et al. (2007) The bacterium, nontypeable Haemophilus influenzae, enhances host antiviral response by inducing Toll-like receptor 7 expression: evidence for negative regulation of host anti-viral response by CYLD. FEBS J 274: 3655-3668.
26. Komatsu K, Jono H, Lim JH, Imasato A, Xu H, et al. (2008) Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. Biochem Biophys Res Commun 377: 763-768.
27. Wang B, Lim DJ, Han J, Kim YS, Basbaum CB, et al. (2002) Novel cytoplasmic proteins of nontypeable Haemophilus influenzae up-regulate human MUC5AC mucin transcription via a positive p38 mitogen-activated protein kinase pathway and a negative phosphoinositide 3-kinase-Akt pathway. J Biol Chem 277: 949-957.
28. Lee J, Komatsu K, Lee BC, Lim JH, Jono H, et al. (2012) Phosphodiesterase 4B mediates extracellular signal-regulated kinase-dependent up-regulation of mucin MUC5AC protein by Streptococcus pneumoniae by inhibiting cAMP-protein kinase A-dependent MKP-1 phosphatase pathway. J Biol Chem 287: 22799-22811.
29. Abraham SM, Clark AR (2006) Dual-specificity phosphatase 1: a critical regulator of innate immune responses. Biochem Soc Trans 34: 1018-1023.
30. Murphy LO, Blenis J (2006) MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31: 268-275.
31. Pannem RR, Dorn C, Ahlqvist K, Bosserhoff AK, Hellerbrand C, et al. (2014) CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 35: 461-468.
32. Sun SC (2010) CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 17: 25-34.
33. Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802: 396-405.
34. McCullough SD, Duncan KE, Swanton SM, Dailey LA, Diaz-Sanchez D, et al. (2014) Ozone Induces a Pro-inflammatory Response in Primary Human Bronchial Epithelial Cells Through MAP Kinase Activation Without NFkappaB Activation. Am J Respir Cell Mol Biol.
35. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, et al. (2003) CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 424: 793-796.
36. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, et al. (2003) The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 424: 801-805.
37. Massoumi R, Chmielarska K, Hennecke K, Pfeifer A, Fassler R (2006) Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 125: 665-677.
38. Koga T, Lim JH, Jono H, Ha UH, Xu H, et al. (2008) Tumor suppressor cylindromatosis acts as a negative regulator for Streptococcus pneumoniaeinduced NFAT signaling. J Biol Chem 283: 12546-12554.
39. Wancket LM, Frazier WJ, Liu Y (2012) Mitogen-activated protein kinase phosphatase (MKP)-1 in immunology, physiology, and disease. Life Sci 90: 237-248.
40. Comalada M, Lloberas J, Celada A (2012) MKP-1: a critical phosphatase in the biology of macrophages controlling the switch between proliferation and activation. Eur J Immunol 42: 1938-1948.
41. Kondo T, Kawai T, Akira S (2012) Dissecting negative regulation of Toll-like receptor signaling. Trends Immunol 33: 449-458.
42. Liu Y, Shepherd EG, Nelin LD (2007) MAPK phosphatases - regulating the immune response. Nat Rev Immunol 7: 202-212.
43. Roberts PJ, Der CJ (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310.
44. Bodai L, Marsh JL (2012) A novel target for Huntington's disease: ERK at the crossroads of signaling. The ERK signaling pathway is implicated in Huntington's disease and its upregulation ameliorates pathology. Bioessays 34: 142-148.